

6-12-2022

Advances in bioprocessing, analytics and formulation of influenza HA-VLP vaccine candidates produced by insect cells

António Roldão
iBET, Portugal

Ricardo Correia
iBET, Portugal

Bárbara Fernandes
iBET, Portugal

Sofia B. Carvalho
iBET, Portugal

Ricardo J. S. Silva
iBET, Portugal

See next page for additional authors

Follow this and additional works at: https://dc.engconfintl.org/vaccine_viii

Recommended Citation

António Roldão, Ricardo Correia, Bárbara Fernandes, Sofia B. Carvalho, Ricardo J. S. Silva, and Cristina Peixoto, "Advances in bioprocessing, analytics and formulation of influenza HA-VLP vaccine candidates produced by insect cells" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022).
https://dc.engconfintl.org/vaccine_viii/29

This Abstract is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Vaccine Technology VIII by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

Authors

António Roldão, Ricardo Correia, Bárbara Fernandes, Sofia B. Carvalho, Ricardo J. S. Silva, and Cristina Peixoto

ADVANCES IN BIOPROCESSING, ANALYTICS AND FORMULATION OF INFLUENZA HA-VLP VACCINE CANDIDATES PRODUCED BY INSECT CELLS

António Roldão, iBET and ITQB-NOVA, Apartado 12, 2781-901 Oeiras, Portugal
aroldao@ibet.pt

Ricardo Correia, iBET and ITQB-NOVA, Apartado 12, 2781-901 Oeiras, Portugal
Bárbara Fernandes, iBET and ITQB-NOVA, Apartado 12, 2781-901 Oeiras, Portugal
Sofia B. Carvalho, iBET and ITQB-NOVA, Apartado 12, 2781-901 Oeiras, Portugal
Ricardo J. S. Silva, iBET and ITQB-NOVA, Apartado 12, 2781-901 Oeiras, Portugal
Cristina Peixoto, iBET and ITQB-NOVA, Apartado 12, 2781-901 Oeiras, Portugal

Key Words: Influenza HA-VLPs, insect cells, evolutionary engineering, process intensification, all-filtration purification

The emergence of new influenza strains demands the continued development of novel, flexible, and scalable platforms for vaccine production. In this study, we describe advancements in the manufacturing process of influenza hemagglutinin (HA)-displaying virus-like particle (VLP)-based vaccines produced by insect cells, from upstream and downstream processing to analytics and formulation.

Aiming to improve influenza HA-VLPs production, evolutionary engineering and process intensification have been applied. Adaptation of stable Sf-9 cells producing HA-VLPs to hypothermic growth resulted in up to 12-fold higher expression. Likewise, adaptation of parental High Five cells to neutral pH induced a 3-fold higher specific HA-VLPs production rate following infection with baculovirus. In both case studies, the adaptation process had no impact on VLPs activity and morphology. Noteworthy, stable adapted Sf-9 cells could be cultured in perfusion (up to 100×10^6 cell/mL) and continuous ($\sim 20 \times 10^6$ cell/mL) operation modes with cell-specific productivity similar to batch mode.

A broadly applicable filtration-based approach was developed to purify HA-VLPs independently of HA group and subtype, and of particle valency (i.e. monovalent or polyvalent VLPs). This strategy uses a cascade of ultrafiltration and diafiltration steps, allowing product recovery of 80%, with improvements in process costs, scalability and time when compared to a standard chromatography-based approach.

The robustness and generic applicability of an array of biophysical and biochemical methods (assessing particle size distribution, purity, surface charge, morphology and thermal stability) for HA-VLPs characterization has been successfully demonstrated. These methods allowed to cope with the different complexity of mono- and penta-valent VLPs, comprising HA from diverse groups (A and B) and subtypes (H1 and H3).

Finally, storage of influenza HA-VLPs was enhanced using a water-free formulation composed of a trehalose-glycerol (TGly) natural-deep eutectic solvent system. TGly allowed to reduce the rate of HA degradation and maintained VLPs' physical integrity upon storage at 50 °C. In addition, HA-VLPs were stable in TGly for slightly over one month at room temperature (20-23 °C), demonstrating the potential of this formulation for storage at non-refrigerated conditions.

Overall, the advancements herein described can be used to assist and/or accelerate influenza HA-VLPs vaccines development.

References:

- Correia, R., et al., 2020. Improving Influenza HA-VLPs Production in Insect High Five Cells via Adaptive Laboratory Evolution. *Vaccines* 8, 589. <https://doi.org/10.3390/vaccines8040589>
- Correia, R., et al., 2021. Improved storage of influenza HA-VLPs using a trehalose-glycerol natural deep eutectic solvent system. *Vaccine* 39, 3279–3286. <https://doi.org/10.1016/j.vaccine.2021.04.033>
- Fernandes, B., et al., 2021. Integrating high cell density cultures with adapted laboratory evolution for improved Gag-HA virus-like particles production in stable insect cell lines. *Biotechnology and Bioengineering* 118, 2536–2547. <https://doi.org/10.1002/bit.27766>
- Fernandes, B., et al., 2020. Adaptive laboratory evolution of stable insect cell lines for improved HIV-Gag VLPs production. *Journal of Biotechnology* 307, 139–147. <https://doi.org/10.1016/j.jbiotec.2019.10.004>
- Carvalho S.B. et al., 2019. Membrane-Based Approach for the Downstream Processing of Influenza Virus-Like Particles. *Biotechnology Journal* 14, 1800570. <https://doi.org/10.1002/biot.201800570>
- Carvalho S.B. et al., 2021. Bioanalytics for Influenza virus-like particles characterization and process monitoring. *Front. Bioeng. Biotechnol. - Bioprocess Engineering*. Accepted for publication.